Navigation Links
Medical Experts Who Participated in CSL Behring's Key Issues Dialogue Prefer Albumin for Fluid Management

KING OF PRUSSIA, Pa., Feb. 21, 2012 /PRNewswire/ -- Thought leaders from the medical community in Europe and the U.S. examined the pros and cons of using albumin in treating liver disease and sepsis, and in cardiac surgery, during CSL Behring's Key Issues Dialogue – "Albumin in Clinical Fluid Management."

(Logo: )

The participants engaged in a frank and provocative exchange about the uses and effectiveness of albumin, which is manufactured from human plasma. Albumin is used to stabilize blood pressure in shock or sepsis patients who may be albumin-deficient. It is also used to treat burn patients and augment fluid replacement therapy in cardiac surgery and in certain liver disorders. The participants discussed other patient benefits of albumin, which is a natural human protein.

Mortality rate reduction

"Albumin reduced the odds of post-paracentesis circulatory dysfunction by 61 percent (in one study)," said Mauro Bernardi, M.D., University of Bologna. "Moreover, for the first time, we were also able to show that albumin reduced mortality rate by 36 percent. We do not have a crystalloid plasma expander that reduces mortality as albumin does." Dr. Bernardi said the reduction in mortality rate in this complication of liver disease is based on a meta-analysis performed by his group at the University.

Education gap

"There is a real need to educate healthcare providers about albumin because its use has changed over time," said Gary R. Haynes, M.D., Ph.D., Saint Louis University School of Medicine, when he addressed some of the current perceptions of albumin. "Even some of the literature for volume resuscitation isn't up-to-date because we have better ways of assessing intravascular volume."

Cost of albumin

The cost of albumin versus crystalloids was also considered. Luciano Gattinoni, M.D., University of Milan, framed the cost issue in this way: "Good medicine means good economy, not vice versa. When physicians are pressed to save money, the potential for complications and adverse events increases."

This Dialogue is the most recent in CSL Behring's ongoing series that analyzes critical issues around human plasma-derived and recombinant coagulation factor therapies for patients, caregivers and healthcare providers.

Garrett E. Bergman, M.D., CSL Behring's Senior Director, Medical Affairs North America, said the Dialogue provided important insights. "Because of our varied disciplines, we've achieved a cross-pollination of ideas that is truly unique," Dr. Bergman said. "As Dr. Bernardi observed during the Dialogue, the fact that we can discuss our respective problems and find so many common points of interest is unusual. It's not often that a pathologist and an intensivist have the opportunity to sit down and exchange ideas and experiences."

About CSL Behring

CSL Behring, a leader in the plasma protein therapeutics industry, has provided the international community with albumin for over 50 years. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation and burn treatment, and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX: CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit or view CSL Limited's Corporate Responsibility Report.

Chris Florentz
Manager, Corporate Communications

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. FasterCures Spotlights Addario Lung Cancer Medical Institutes Innovative Research Programs
2. Johns Hopkins Health System is 100th healthcare Provider to Integrate OnBase With Leading Electronic Medical Record System
3. Spherix to Present at the LHA Life Sciences & Medical Technologies Virtual Conference on February 16
4. The butterfly effect in nanotech medical diagnostics
5. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
6. PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs
7. Rap music powers rhythmic action of medical sensor
8. ZyGEM to Provide its Unique DNA and RNA Extraction Technology to Middle East Biomedical Innovator Saudi Diagnostics Ltd.
9. Survey: Small Medical Practice Confidence Index Rises in 2012
10. Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board
11. UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... ... that includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, awards, ... spectroscopy, covers a wide range of applications such as, but not limited to, ...
(Date:11/25/2015)... , November 26, 2015 ... Biobanking Market 2016 - 2020 report analyzes that ... integrity and quality in long-term samples, minimizing manual ... cost-effectiveness. Automation minimizes manual errors such as mislabeling ... efficiency. Further, it plays a vital role in ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. 25, ... HART ), a biotechnology company developing bioengineered organ ... Jim McGorry will present at the LD Micro ... at 2:30 p.m. PT. The presentation will be webcast ... days. Management will also be available at the conference ...
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015 ... that management will participate in a fireside chat discussion ... New York . The discussion is ... Time. .  A replay will ... Contact:  Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015 ... biometrics that helps to identify and verify the ... is considered as the secure and accurate method ... of a particular individual because each individual,s signature ... results especially when dynamic signature of an individual ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
(Date:10/29/2015)... Oct. 29, 2015  Rubicon Genomics, Inc., today ... distribution of its DNA library preparation products, including ... new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been ... of NGS libraries for liquid biopsies--the analysis of ... prognostic applications in cancer and other conditions. Eurofins ...
Breaking Biology News(10 mins):